HRES 342 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes.
Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes.
Summary
- Expresses support for designating April 20 through 26, 2025 as "DES Awareness Week."
- Recognizes the history of diethylstilbestrol (DES) and the harm it has caused to millions of people.
- Supports restoration of funding for the DES Follow-Up Study.
- Urges the Food and Drug Administration to issue a formal apology to families impacted by diethylstilbestrol.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
-
![Rep. McGovern, James P. [D-MA-2]](https://media.civicgate.org/people/d/politicians/M000312.thumb.jpg)
Rep. McGovern, James P. (D-MA) [#2]
Money behind the sponsor
Top reported contributors to James P. Mcgovern’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- Employer not reported $16,700
- DRAGONFLY $9,900
- TUSK HOLDINGS $6,600
- GFP REAL ESTATE $6,600
- NIRVANAHEALTH $6,600
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for James P. Mcgovern → · Outside spending →
Actions (2)
- Apr 21, 2025 Referred to the House Committee on Energy and Commerce. · house
- Apr 21, 2025 Submitted in House
More bills on these subjects (8)
Other bills that carry the most legislative subjects in common with this one (topical discovery — distinct from the procedural related bills above).
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
April 21, 2025
Mr. McGovern submitted the following resolution; which was referred to the Committee on Energy and Commerce
RESOLUTION
Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes.
Whereas diethylstilbestrol (“DES”) is a toxic and carcinogenic estrogen and endocrine disrupter; Whereas the Food and Drug Administration (“FDA”) approved DES in the early 1940s; Whereas DES was widely prescribed, with the intention of preventing miscarriage, to between five and ten million pregnant women in the United States until 1971; Whereas DES exposure in utero was linked to the development of rare cancers of the vagina and cervix called clear cell adenocarcinoma in female children, commonly referred to as “DES Daughters”; Whereas the FDA banned the use of DES during pregnancy in the United States in 1971; Whereas DES exposure in utero has since been linked to increased fertility and pregnancy complications and other physical and mental health challenges; Whereas the FDA has acknowledged the harm caused by DES but has yet to apologize to the families of those impacted by its prolonged use; and Whereas April 20 through 26, 2025, would be an appropriate week to designate as “DES Awareness Week”: Now, therefore, be it Resolved, That the House of Representatives—
(1) expresses support for the designation of “DES Awareness Week”;
(2) recognizes the history of the drug diethylstilbestrol and the harm it has caused;
(3) supports the restoration of funding for the DES Follow- Up Study; and
(4) urges the Food and Drug Administration to issue a formal apology to families impacted by diethylstilbestrol. <all>
Comments